£25m · Series A · Healthtech · London, UK
Alchemab Therapeutics has added £25m to its Series A in an extension from the British Business Bank. The investment, the bank's largest direct life sciences investment to date, takes the clinical-stage biotech's total Series A financing to £109m.
Mining natural resilience for therapeutic antibodies
Alchemab studies antibodies found in people who remain resilient to disease, looking for naturally occurring protective responses that can be developed into medicines. Its Resiliome platform combines deep immune sequencing, computational analysis and laboratory validation. The company says the platform contains more than half a billion antibody sequences.
The new capital will support further research, expand that proprietary dataset and advance two wholly owned programmes toward the clinic. That gives Alchemab financing for both sides of its model: a broader discovery engine and the costly translational work needed to turn candidates into clinical assets.
The platform has already produced ATLX-1282, an antibody programme for amyotrophic lateral sclerosis that Alchemab licensed to Eli Lilly in 2025. The asset entered clinical development within three years of discovery, providing an early test of whether the company's resilience-led discovery approach can move from large-scale antibody data to drug candidates on a practical timeline.
A state-backed vote of confidence in UK biotech
The £25m extension comes from a single state-backed investor, rather than a new syndicate. Previous Series A investors include SV Health Investors, RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment and Camford Partners. For the British Business Bank, the deal is a deliberate effort to supply long-duration growth capital to a UK life sciences company; for Alchemab, it reduces the funding gap between platform discovery and clinical proof.
The commercial question now shifts from database scale to pipeline conversion. Expanding beyond half a billion sequences can create more discovery opportunities, but value depends on selecting targets, validating antibodies and progressing wholly owned programmes through the clinic. The £109m Series A gives Alchemab more runway to demonstrate that conversion while retaining economics in assets it has not licensed out.
Sources checked:
Alchemab Therapeutics · British Business Bank · Alchemab locations · Tech.eu Funding Explorer
